Denali Therapeutics (DNLI) Shares Issued (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Shares Issued data on file, last reported at $12.4 million in Q1 2026.

• Shares Issued for Q1 2026 came in at $12.4 million, up 1978.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.2 million (up 19.27% YoY), and the FY2025 annual result was $8.5 million, down 51.35% from the prior year.
• Shares Issued rose to $12.4 million in Q1 2026 per DNLI's latest filing, from $8.5 million in the prior quarter.
• Over five years, Shares Issued peaked at $285.2 million in Q4 2022 and troughed at -$595000.0 in Q2 2025.
• A 5-year average of $25.2 million and a median of $4.9 million in 2022 frame the typical range for Shares Issued.
• The sharpest annual moves came in 2022 and 2025: Shares Issued surged 5418.5% in 2022, then slumped 108.81% in 2025.
• A 5-year view of Shares Issued shows it stood at $285.2 million in 2022, then slumped by 98.35% to $4.7 million in 2023, then declined by 11.69% to $4.2 million in 2024, then jumped by 103.59% to $8.5 million in 2025, then jumped by 46.19% to $12.4 million in 2026.
• Business Quant data shows DNLI's Shares Issued at $12.4 million in Q1 2026, $8.5 million in Q4 2025, and -$595000.0 in Q2 2025.